Oral manifestations, salivary flow rates and Candida species in Thai HIV-infected patients by Lam-ubol, Aroonwan et al.
J Clin Exp Dent. 2019;11(2):e138-45.                                                                                                                                                                                        Oral conditions of HIV-infected patients
e138
Journal section: Oral Medicine and Pathology                         
Publication Types: Research
Oral manifestations, salivary flow rates and Candida 
species in Thai HIV-infected patients 
Aroonwan Lam-ubol 1, Sorasun Rungsiyanont 1, Piamkamon Vacharotayangul 1, Kraisorn Sappayatosok 2, 
Oitip Chankanka 3
1 Faculty of Dentistry, Srinakharinwirot University, 114 Sukhumvit 23, Wattana, Klongtoey Nua, Bangkok 10110, Thailand
2 Faculty of Dentistry, Rangsit University, 52/347 Phaholyothin Road, Mueang Pathum Thani District, Pathum Thani 12000, Thai-
land
3 Faculty of Dentistry, Prince of Songkla University, 15 Karnjanavanich Raod, Hat Yai, Songkhla 90110, Thailand
Correspondence:
Department of Oral Surgery and Oral medicine
Faculty of Dentistry
Srinakharinwirot University, Sukhumvit 23
Wattana, Bangkok 10110, Thailand
aroonwan@gmail.com




Background: Effects of various Highly Active Antiretroviral Therapy (HAART) regimens on oral heath are unclear. 
Objectives: We aimed to evaluate effects of HAART on oral manifestations, salivary flow rates (SFR) and Candida 
species in HIV-infected patients who took mostly non-protease inhibitor-based HAART regimens.
Material and Methods: A cross-sectional study was performed on HIV-infected patients taking and never taken 
HAART who attended Thai Red Cross AIDS Research Centre (n = 48). Non-HIV subjects were recruited as control 
(n = 20). Oral conditions and salivary flow rates were evaluated using oral examination and measurement of unsti-
mulated and stimulated saliva. In addition, Candida colonization counts (colony forming units; CFUs) and Candida 
species from the collected saliva were evaluated using CHROMagar. 
Results: The most common oral manifestation in HIV-infected subjects taking HAART was hyperpigmentation. 
Unstimulated and stimulated SFR among the three groups were not statistically significant. Candida coloniza-
tion was detected in 64%, 65% and 35% of HIV-infected subjects taking HAART, HAART-naïve, and non-HIV 
subjects, respectively. While 20% and 35% of HIV-infected subjects with and without HAART, respectively, had 
Candida CFUs higher than 500/ml, all non-HIV carriers had Candida CFUs lower than 500/ml. The most common 
Candida colonization species was C. albicans in HAART and non-HIV groups. Interestingly, HAART-naïve group 
was colonized more by non-albicans species.
Conclusions: HAART has minimal effects on oral health. While HAART may not prevent Candida colonization, 
it might lead to reduction of non-albicans species. Because maintaining low Candida counts is important, HAART 
administration and antifungal sensitivity test should be considered in HIV-infected patients.
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Introduction
Human Immunodeficiency Virus (HIV) infection has 
been one of the major public health problems. Accor-
ding to UNAIDS, it was estimated that 36.9 million peo-
ple were living with HIV worldwide in 2017. Although 
HIV infection caused high mortality and morbidity in 
the past, the disease has been better controlled since 
the introduction of Highly Active Antiretroviral Thera-
py (HAART) in 2000 (1-3). HIV-infected patients are 
now living longer. Trends of diseases have been chan-
ged with significant decrease in opportunistic infec-
tions. However, patients living with AIDS face other 
health problems such as lipodystrophy, cardiovascular 
diseases and cancers, due to the disease itself and side 
effects from HAART (4). Oral side effects of HAART 
have been reported, such as hyperpigmentation, salivary 
gland hypofunction, salivary gland enlargement and 
human papillomavirus infection (1,5). Since then, the-
re have been changes in HAART regimen to maximize 
antiviral effects and minimize adverse effects. Non-nu-
cleoside reverse transcriptase inhibitor (NNRTI)-contai-
ning regimens offer superior virological suppression and 
better immunological outcome than protease-inhibitor 
(PI)-containing regimens (2,6,7). Most current first line 
regimens worldwide, including Thailand, had shifted 
from PI-containing regimens to NNRTI-containing re-
gimens (1,2,8,9).
Oral candidiasis, one of the most common opportunistic 
infection in HIV-infected patients, has been significantly 
reduced with HAART (1-3). Effects of HAART on Can-
dida colonization in HIV-infected patients is still contro-
versial (8-10). Although Candida species can normally 
colonize in the oral cavity without clinical symptoms, 
increased numbers of Candida colonization had been 
shown to promote risk of oral candidiasis (11, 12). Oral 
cavity colonization by Candida species can be found 
in healthy population, however, percentage of Candida 
carriers in HIV-infected patients were reported to be hi-
gher than in healthy population (8). Candida albicans is 
the most common species found in oral candidiasis and 
Candida colonization in HIV-infected subjects. Howe-
ver, there has been an increase in non-albicans species in 
this population (13-15). PIs were shown to have inhibi-
tory effects against Candida (16). However, NRTIs and 
NNRTIs are used more frequently nowadays. Previous 
studies showed inconsistent results about incidences in 
developing oral candidiasis between NNRTI-users and 
PI-users (2,17). In addition, effects of HAART on Can-
dida colonization and Candida species were unclear. 
Objectives
Studies on effects of HAART on oral changes, Candida 
species and salivary gland function had been reported 
from several countries, including Thailand, with various 
results (1,18). These could be because differences in 
study population, HAART regimens and study methods. 
The objective of this study was to evaluate effects of 
HAART on oral manifestations, Candida colonization 
species and salivary flow rates in Thai HIV-infected pa-
tients.
Material and Methods
-Study design and participants
This was a cross-sectional study performed in patients 
infected with HIV who attended the Thai Red Cross 
AIDS Research Centre. Both patients receiving HAART 
and never received HAART (HAART-naïve) were re-
cruited. In addition, control group included non-HIV-in-
fected subjects recruited from the Faculty of Dentistry, 
Srinakharinwirot University, Bangkok, Thailand. The 
study protocol was approved by the ethical review 
boards of the Faculty of Medicine, Chulalongkorn Uni-
versity and Faculty of Dentistry, Srinakharinwirot Uni-
versity. All subjects were informed of the objectives and 
study protocol, and gave written consent prior to partici-
pate in the study. All non-HIV-infected subjects received 
blood test to confirm HIV-seronegativity. Subjects who 
had oral candidiasis or systemic or local treatment with 
antifungals within the previous three months were ex-
cluded from the study. 
-Data collection
The following data were collected from the HIV-infec-
ted subject’s medical records: personal information, me-
dical history and results from laboratory tests (the clo-
sest ones to the time of sample collection), CD4 counts, 
viral load, diagnosis of AIDS, antiretroviral therapy, and 
use of antifungal or other medication. Subjects were ins-
tructed not to eat or drink for one hour prior to sample 
collection. Subjects were then interviewed regarding 
dental problems. Oral and dental structures were exa-
mined and recorded by oral medicine specialists. Un-sti-
mulated and mechanical-stimulated saliva samples were 
collected by using standard protocol. For un-stimulated 
saliva, the subjects were asked to rinse their mouth with 
water. Then, after swallowing all the saliva present in 
the mouth, they were instructed to allow new saliva to 
accumulate in the mouth, and expectorate it into a 50 ml 
tube that was previously weighed every 60 seconds for a 
period of 5 minutes. For stimulated saliva, subjects were 
asked to chew on a piece of paraffin (1 gram) and ex-
pectorate whole stimulated saliva into a 50 ml tube for 5 
minutes.  Salivary flow rates were calculated as ml/min. 
After collection, the saliva was kept at 4 degrees Celsius 
and used for analysis within 6 hours.
-Analysis of Candida counts and species
The saliva samples were centrifuged and supernatants 
were used for the analysis. Each saliva sample was di-
luted 1:10 with phosphate buffered saline pH 7.2 and 
cultured on CHROMagar Candida plates (CHROMa-
gar Microbiology) in an incubator at 37 degrees Cel-
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sius. Colony forming units (CFUs) and colony color 
and morphology were evaluated after 48 hours. CFUs 
were classified as low (less than 500 CFUs/ml) and high 
(more than 500 CFUs/ml). Candida colonies were cha-
racterized based on color according to the manufactu-
rer’s recommendation (C. albicans: green, C. tropicalis: 
metallic blue, C. krusei: pink, fuzzy, other species: white 
to mauve). Plates exhibiting no growth were incubated 
for another 24 hours to confirm the absence of Candida 
colonies.
-Statistical analysis
Demographic data and salivary flow rates of HIV-in-
fected subjects taking HAART, HIV-infected subjected 
not taking HAART (HAART-naïve) and non-HIV-infec-
ted subjects were compared using Independent Sample 
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-Demographic data of the study population
A total of sixty-eight subjects were included in the 
study. Twenty-five (36.8%) and 23 (33.8%) of them 
were HIV-infected patients who received HAART 
and HAART-naïve, respectively. Twenty (29.4%) 
non-HIV-infected subjects were included as control 
group.
Average age and sex of subjects in the three groups were 
not statistically significant (Table 1). Duration of HIV 
infection ranged from 2 to 18 years with an average of 
8.5 years in a group taking HAART and 6.7 years in a 
HAART-naïve group. Average CD4 counts in a HIV-in-
fected groups taking HAART and HAART-naïve were 
513+193 and 425+183 cells per ml, respectively. Al-
though CD4 counts in HAART-naïve group were signifi-
cantly lower (p=0.03), all subjects had CD4 counts more 
Table 1: Demographic data of study population.
*Independent Sample Kruskal-Wallis test
**Mann-Whitney U Test
***Chi-square
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than 200 cells per ml. As expected, average viral loads in 
HIV-naïve subjects (16,285 copies per ml) were higher 
than HIV-infected subjects taking HAART (lower than 
40 copies per ml). Regarding HAART regimens, majori-
ty (88%) of HIV-infected subjects received combination 
of NRTIs and NNRTIs. Only 3 HIV-infected subjects 
(12%) received combination of NRTIs and PIs. Average 
duration of HAART usage was 5.7 years, ranging from 
0.6-13.8 years. Most subjects (80%) had taken HAART 
for longer than 5 years.
-Oral and dental findings
Oral lesions observed among HIV-infected subjects 
included dry mouth and hyperpigmentation. Notably 
40% of subjects taking HAART demonstrated hyper-
pigmentation of oral mucosa, while no hyperpigmen-
tation was found in HAART-naïve subjects.  Signs of 
dry mouth were noted in 20% of HIV-infected subjects 
taking HAART and 4.3% of HAART-naïve subjects. 
Other lesions included aphthous ulcer, smoking-indu-
ced leukoplakia, nicotinic stomatitis, traumatic ulcer 
and coated tongue as shown in Table 2. Noted that these 
other lesions, except coated tongue, were only observed 
in HIV-infected subjects taking HAART. However, the 
numbers were low and may not be of clinical signifi-
cance.
Manifestations Numbers, %
HIV with HAART HIV, HAART-naïve
Dry mucosa 5, 20% 1, 4.3%
Pigmentation 10, 40% 0
Aphthous ulcer 1, 4% 0
Smoking leukoplakia 1, 4% 0
Nicotinic stomatitis 1, 4% 0
Traumatic ulcer 1, 4% 0
Coated tongue 1, 4% 3, 13%
Table 2: Oral manifestations in HIV-infected subjects.
-Salivary flow rates
Unstimulated salivary flow rates in non-HIV infected 
subjects (0.60+0.3 ml/min) were higher than HIV-in-
fected groups taking HAART (0.53+0.2 ml/min) and 
HAART-naïve (0.48+2.2 ml/min). On the other hand, 
stimulated salivary flow rates in HAART-naïve HIV-in-
fected subjects (3.11+2 ml/min) were higher than non-
HIV infected subjects (2.6+1.1 ml/min) and HIV-in-
fected subjects taking HAART (2.34+0.8 ml/min). The 
summary of data is shown in Table 3. However, the di-
fference was not statistically significant. 
-Candida counts and factors affecting Candida colonization
Percentage of Candida carriers in HIV-infected sub-
jects taking HAART and HAART-naïve were 64% and 
65%, respectively, which were higher than those in 
non-HIV-infected subjects (35%). In addition, Candida 
CFUs in all non-HIV-infected subjects were lower than 
500 CFUs/ml. On the other hand, 20% of HIV-infected 
subjects taking HAART and 35% of HAART-naïve sub-
jects had CFUs more than 500 CFUs/ml. The summary 
of data is shown in Figure 1. When we evaluated factors 
that might affects Candida colonization in each group, 
no statistically difference was found in any factors, in-
cluding CD4 counts, years of HIV infections, years of 
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Table 3: Salivary flow rates (SFR) of study populations.
*Independent Sample Kruskal-Wallis test.
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Fig. 1: Candida carriers and Candida counts in non-HIV, HIV-infected subjects who never 
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Table 4: Comparisons of factors between Candida carrier and non-carriers.
* Kruskal-Wallis test
**Mann-Whitney U Test
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-Candida species
Regarding Candida species, HIV-infected subjects with 
HAART were colonized by C. albicans alone (32%) 
more than mixture between albicans and non-albicans 
(20%) and non-albicans alone (12%). The profile was si-
milar to non-HIV infected subjects who were colonized 
mostly by C. albicans alone (15%) and mixture between 
albicans and non-albicans (15%). On the other hand, 
majority of Candida carriers in HAART-naïve group 
were colonized by non-albicans alone (26%) and mixtu-
re between albicans and non-albicans (26%). Only 13% 
of them were colonized by C. albicans alone. All non-al-
bicans species identified in this study demonstrated whi-
te colonies, meaning that they were other species than C. 
tropicalis and C. krusei. The summary of data is shown 
in Figure 2. This data suggests that HAART usage and 
HIV infection might affect Candida colonization profile.
Fig. 2: Candida species colonization in non-HIV, HIV-infected subjects who never taken and taking 
HAART, respectively.
Discussion and conclusion
This cross-sectional study evaluated effects of HIV in-
fection and current HAART regimen on oral conditions 
and Candida colonization in Thai population.
We found that current HAART regimens in majority of 
our population were combination of NRTIs and NNR-
TIs, which were different than previously used PIs. This 
regimen is consistently used nowadays due to reported 
better virological controls than PIs (6,7). Similar to pre-
vious studies, we found that hyperpigmentation is com-
mon among HAART users as compared to HAART-naï-
ve and non-HIV-infected subjects. This is not surprising, 
as hyperpigmentation is a known side effect of HAART 
and has been reported (1,19). Other oral lesions were 
few, in accordance to some previous studies (1,19). Ano-
ther study from Thailand showed higher percentages of 
oral lesions than our study. However, their subjects had 
higher viral load levels and lower CD4 counts than our 
subjects (1). One reason could be because our popu-
lation received HAART early in their disease courses. 
This assumption is supported by recent study, which re-
vealed that early administration of HAART when CD4 
is lower than 350 cells/ml reduced incidence of oral 
lesions when compared to late administration (when 
CD4 is lower than 200 cells/ml) (20). Consistent with 
previous study in Thailand, we did not find any wart or 
Human Papillomavirus (HPV)-induced lesion in this 
population (1). Interestingly, our previous study showed 
that HIV-infected individuals had higher prevalence of 
HPVs, especially high-risk HPVs, detected from their 
oral rinses even without visible lesions (21). Long-term 
study for prevalence of HPV-associated lesions, inclu-
ding oropharyngeal cancer will be of value. 
The prevalence of xerostomia and salivary gland hypo-
function has been reported to be 2% to 10% in HIV in-
fected patients (5,22). In addition, previous studies show 
that PIs led to significant effect on salivary gland func-
tion (4,5). On the other hand, continue treatment with 
non-PI HAART will improve salivary flow rates (5,23). 
We noted that percentage of HAART users with signs of 
dry mouth was not different from that of HAART-naï-
ve (24% vs 17.3%). Moreover, salivary flow rates were 
not statistically different among the three groups. In our 
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study, none of HIV-infected subjects had hyposalivation 
(less than 0.1 ml/min for unstimulated salivary flow rate 
and less than 0.7 ml/min for stimulated salivary flow 
rate). This could be because majority of subjects were 
long-term users of non-PI-based HAART regimens. 
Consistent with previous studies, this HAART regimen 
seems to have little effects to salivary gland function 
(5,23). However, study by the other group in Thailand 
showed that salivary flow rates of HAART users were 
significantly lower than non-HAART users (1). This 
could be due to differences in saliva collection, HAART 
regimen and study population. In addition, some of their 
population had CD4 levels lower than 200 cells/ml, 
which had been reported to affect salivary gland func-
tion in HAART users (1,24). 
Our study showed that HIV-infected subjects had higher 
percentage of Candida carriers and Candida counts, re-
gardless of HAART status. Percentages of Candida ca-
rriers in our study were 64% and 65% in HIV-infected 
subjects taking and not taking HAART, respectively. On 
the other hand, 35% of Candida carriers were detected 
in healthy control group. In addition, Candida coloni-
zation CFUs in HIV-infected subjects were higher than 
those in healthy subjects. The findings were similar to 
previous studies which demonstrated that Candida ca-
rriers in HIV-infected subjects ranged from 42-57% 
(8,9,15). Previous study in Thailand reported 56.6% 
Candida carriers in HIV-infected subjects (9). Previous 
studies have shown that HAART decreased the inciden-
ce of all HIV-related opportunistic infections including 
fungal infection, but there are conflicting reports regar-
ding the association between oral yeast colonization and 
HAART. While some studies, including ours, showed no 
protective effects of HAART on Candida colonization, 
some studies reported decreased in Candida coloniza-
tion in HAART users, particularly those with PI-based 
regimens (8-10,14,17). These could be due to differen-
ces in study population, HAART regimen and fungal 
identification methods. 
While antifungal mechanism of PIs, due to its ability 
to inhibit fungal secretory aspartyl proteinases (16), is 
well-known, that of non-PI-based HAART is not clearly 
understood. Because CD4 levels lower than 200 cells/ml 
were one of the risk factors of Candida colonization, an-
tifungal ability of non-PI-based HAART could be indi-
rectly due to restoration of CD4 levels (15). In our study, 
although CD4 levels of subjects in HAART-naïve group 
were significantly lower than those in HAART group, 
all population had CD4 levels higher than 200 cells/ml. 
This could explain why we did not see effect of HAART 
on Candida colonization in our population. Table 5 re-
veled that salivary flow rates and other factors did not 
affect Candida colonization. Other factors might affect 
-Candida colonization in our population.
Candida colonization profile observed in our study was 
similar to other studies. Studies in many countries, in-
cluding Brazil, Thailand, China, demonstrated that C. 
albicans was the most common species in both healthy 
and HIV-infected Candida carriers. Variety of non-albi-
cans species had been detected in HIV-infected Candida 
carriers from 20% to 50% (8,9,25). In addition, mixed 
colonization had been identified from 7% to 41% (8,9). 
Percentage of Candida species colonization from our 
findings were within the ranges previously reported. In-
terestingly, colonization by non-albicans and mixed spe-
cies were observed in healthy subjects. Similar findings 
were also previously described (8,9). 
Risk factors for non-albicans colonization are contro-
versial and include reduced CD4 counts (less than 200 
cells/ml), use of antibiotics and antifungal drugs, his-
tory of tuberculosis, contraceptive use and HIV infec-
tion (9,26,27). In our study, HAART-naïve HIV-infected 
subjects were colonized more by non-albicans species. 
This study showed that although the use of HAART did 
not reduce Candida colonization and Candida counts, it 
led to reduction of non-albicans colonization. This was 
in accordance with previous studies that NRTIs and NN-
RTIs also had antifungal activity with unknown mecha-
nism (2,7). In addition to antifungal effects of HAART, 
restoration of CD4 levels might contribute to the reduc-
tion of non-albicans colonization (26). 
Although the role of non-albicans and mixed Candi-
da colonization in HIV-infected individual is not clear, 
non-albicans species were shown to be more resistant 
to conventional antifungal drugs (28,29). In addition, 
mixed infection may make drug resistance more com-
plicated (30). Due to the limited availability of data, cer-
tain factors could not be investigated in this study for 
their impact. Use of contraceptive, particular HAART 
regimens, history of tuberculosis, nutritional status and 
drug abuse might affect Candida colonization. Future 
study to identify Candida species in larger population 
and drug sensitivity test will be beneficial.
In conclusion, our study demonstrated that HIV-infected 
subjects had higher chance to be Candida carriers and 
contained higher numbers of Candida colonization than 
healthy subjects. In addition, HAART usage reduced 
colonization by non-albicans species. Because maintai-
ning low Candida counts in this population is important, 
early HAART administration and appropriate antifungal 
drugs should be considered in HIV-infected patients.
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